Farshid Dayyani, MD
Enriched profileProfessor of Clinical Medicine, Division of Hematology/Oncology; Medical Director, Stern Center for Cancer Clinical Trials & Research; Associate Director for Translational Science, Chao Family Comprehensive Cancer Center · University of California, Irvine
Farshid Dayyani is Professor of Clinical Medicine, Division of Hematology/Oncology; Medical Director, Stern Center for Cancer Clinical Trials & Research; Associate Director for Translational Science, Chao Family Comprehensive Cancer Center at University of California, Irvine. OpenAlex indexes 296 publications with 7,616 citations (h-index 37); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Farshid Dayyani, MD, PHD, is Professor of Clinical Medicine, Division of Hematology/Oncology at University of California, Irvine (UC Irvine School of Medicine / UCI Health). The public record shows 296 publications with 7,616 citations (h-index 37), centered on Gastroesophageal Cancer, Hepatobiliary Cancer, Colorectal Cancer. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 22 companies.
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Gastroesophageal Cancer
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 39 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu
Sponsor: University of California, Irvine
- Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 27 Aug 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year202547 payments$98,408openpaymentsdata.cms.gov ↗
- Astellas Pharma US IncProgram year202546 payments$77,691openpaymentsdata.cms.gov ↗
- Sirtex Medical IncProgram year202532 payments$47,217openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
42.3%Serotonin-3 Receptor Antagonist20.7%Ondansetron Hcl84%Ondansetron Odt16%Part D<11 patientsPotassium supplement5.1%Potassium Chloride100%Part D≥12 patientsNervous system
33.7%Phenothiazine22.7%Prochlorperazine Maleate100%Part D≥47 patientsAtypical Antipsychotic11%Olanzapine100%Part D≥19 patientsSensory organs
8.9%Corticosteroid8.9%Dexamethasone69%Clobetasol Propionate31%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial.
Future oncology (London, England)
Clinical Trial2026
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/farshid-dayyani-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/farshid-dayyani-md-phd-a30921104
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Farshid-Dayyani
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/reel/C6rPrsdJDYP
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Instagram
instagram.com/reel/C8setLxSBya
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - LinkedIn
linkedin.com/posts/anticancerchallenge_meet-dr-farshid-dayyani-whose-projects-have-activity-7193673098443853824-_UfD
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.uci.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.uci.edu ↗
- Internal Medicine Residency
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →clinicalconnection.ucihealth.org ↗ - Medical Oncology Fellowship (clinical and research)
University of Texas MD Anderson Cancer Center, Houston, TX
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →clinicalconnection.ucihealth.org ↗ - Board Certified
Medical Oncology, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucihealth.org ↗
Editorial & leadership roles
journal and society appointments- Member
American Society of Clinical Oncology (ASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.uci.edu ↗ - Member
Medical Oncology Association of Southern California (MOASC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.uci.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucihealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucihealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucihealth.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.uci.edu ↗
- Sue & Bill Gross Stem Cell Research Center
UC Irvine - affiliated faculty
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →stemcell.uci.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →learn.colontown.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗
- "Conversations on CCA" video series
CCA News Online - discussed managing cholangiocarcinoma during COVID-19
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ccanewsonline.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Susan O’Brien, MD
University of California, Irvine
Steven Potkin, MD
University of California, Irvine
Mitchell Brin, MD
University of California, Irvine
Deborah Wing, MD
University of California, Irvine